90 related articles for article (PubMed ID: 10476930)
1. Low-dose oral use of interferon inhibits virally induced myocarditis.
Lawson CM; Beilharz MW
J Interferon Cytokine Res; 1999 Aug; 19(8):863-7. PubMed ID: 10476930
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo.
Bosio E; Beilharz MW; Watson MW; Lawson CM
J Interferon Cytokine Res; 1999 Aug; 19(8):869-76. PubMed ID: 10476931
[TBL] [Abstract][Full Text] [Related]
3. Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.
Bartlett EJ; Cull VS; Brekalo NL; Lenzo JC; James CM
Immunol Cell Biol; 2002 Oct; 80(5):425-35. PubMed ID: 12225378
[TBL] [Abstract][Full Text] [Related]
4. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo.
Beilharz MW; McDonald W; Watson MW; Heng J; McGeachie J; Lawson CM
J Interferon Cytokine Res; 1997 Oct; 17(10):625-30. PubMed ID: 9355964
[TBL] [Abstract][Full Text] [Related]
5. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice.
Cull VS; Broomfield S; Bartlett EJ; Brekalo NL; James CM
Gene Ther; 2002 Oct; 9(20):1369-78. PubMed ID: 12365002
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus.
Sonnenfeld G; Tovey M; Schellekens H; Kinney KS; Belay T; Morton DS; Austin CE; Reitman M; Fong TA; Vaughan HS
J Interferon Cytokine Res; 2001 Jul; 21(7):539-45. PubMed ID: 11506749
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of tacrolimus and human interferon-alpha A/D in murine viral myocarditis.
Kanda T; Nagaoka H; Kaneko K; Wilson JE; McManus BM; Imai S; Suzuki T; Murata K; Kobayashi I
J Pharmacol Exp Ther; 1995 Jul; 274(1):487-93. PubMed ID: 7542339
[TBL] [Abstract][Full Text] [Related]
8. Oromucosal interferon therapy: marked antiviral and antitumor activity.
Tovey MG; Maury C
J Interferon Cytokine Res; 1999 Feb; 19(2):145-55. PubMed ID: 10090400
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Chinese herbal medicine Xin-kang oral liquid on interferon-induction and its antiviral activity in coxsackievirus B3 infected mice].
Wan SJ; Li JN; Zhao H; Wang LX; Huang XZ; Zhu Y; Chen HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Mar; 19(1):77-9. PubMed ID: 16201482
[TBL] [Abstract][Full Text] [Related]
10. In vivo characterization of cytokine profiles and viral load during murine cytomegalovirus-induced acute myocarditis.
Ritter JT; Tang-Feldman YJ; Lochhead GR; Estrada M; Lochhead S; Yu C; Ashton-Sager A; Tuteja D; Leutenegger C; Pomeroy C
Cardiovasc Pathol; 2010; 19(2):83-93. PubMed ID: 19217318
[TBL] [Abstract][Full Text] [Related]
11. Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus.
Yamamoto N; Shibamori M; Ogura M; Seko Y; Kikuchi M
Circulation; 1998 Mar; 97(10):1017-23. PubMed ID: 9529271
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.
Tompkins WA
J Interferon Cytokine Res; 1999 Aug; 19(8):817-28. PubMed ID: 10476925
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the immunomodulatory and antiviral effects of the cytokine combination IFN-α and IL-7 in the lymphocytic choriomeningitis virus and Friend retrovirus mouse infection models.
Audigé A; Hofer U; Dittmer U; van den Broek M; Speck RF
Viral Immunol; 2011 Oct; 24(5):375-85. PubMed ID: 21929334
[TBL] [Abstract][Full Text] [Related]
14. Oral-mucosal administration of IFN-alpha potentiates immune response in mice.
Nagao Y; Yamashiro K; Hara N; Horisawa Y; Kato K; Uemura A
J Interferon Cytokine Res; 1998 Sep; 18(9):661-6. PubMed ID: 9781804
[TBL] [Abstract][Full Text] [Related]
15. Oral use of interferon.
Cummins JM; Beilharz MW; Krakowka S
J Interferon Cytokine Res; 1999 Aug; 19(8):853-7. PubMed ID: 10476928
[TBL] [Abstract][Full Text] [Related]
16. Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide.
Bahr GM; Pouillart PR; Chedid LA
J Interferon Cytokine Res; 1996 Apr; 16(4):297-306. PubMed ID: 9162523
[TBL] [Abstract][Full Text] [Related]
17. [Effect of shen-dong-xin-bao oral liquid on IFN-induction and NK cell activity in CVB3m infected mice].
Wan S; Li J; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Mar; 13(1):27-8. PubMed ID: 12759947
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of murine cytomegalovirus myocarditis: cellular infiltration of the heart and virus persistence.
Lenzo JC; Fairweather D; Cull V; Shellam GR; James Lawson CM
J Mol Cell Cardiol; 2002 Jun; 34(6):629-40. PubMed ID: 12054850
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication.
Yeow WS; Lawson CM; Beilharz MW
J Immunol; 1998 Mar; 160(6):2932-9. PubMed ID: 9510197
[TBL] [Abstract][Full Text] [Related]
20. Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease.
Ilbäck NG; Wesslén L; Pauksen K; Stålhandske T; Friman G; Fohlman J
Scand J Infect Dis Suppl; 1993; 88():117-23. PubMed ID: 8390714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
